COVID-19 Vaccines and Treatment Protocols


  • EMA recommends standard marketing authorisations for Comirnaty and Spikevax COVID-19 vaccines , 21-09-2022
  • Adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 recommended for approval , 13-09-2022
  • ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines , 09-09-2022
  • COVID-19: recommendations on use of adapted vaccines , 09-09-2022
  • First adapted COVID-19 booster vaccines recommended for approval in the EU , 02-09-2022
  • EMA starts review of conditional marketing authorisation application for Skycovion COVID-19 vaccine , 19-08-2022
  • EMA reviewing data on sabizabulin for COVID-19 , 29-07-2022
  • ECDC and EMA update recommendations on additional booster doses of mRNA COVID-19 vaccines , 12-07-2022
  • Updated joint statement from ECDC and EMA on additional booster doses of COVID-19 vaccines , 12-07-2022
  • EMA recommends Valneva’s COVID-19 vaccine for authorisation in the EU , 24-06-2022
  • EMA recommends authorisation of Nuvaxovid for adolescents aged 12 to 17 , 24-06-2022
  • Start of rolling review for adapted Spikevax COVID-19 vaccine , 20-06-2022
  • Start of rolling review for adapted Comirnaty COVID-19 vaccine , 16-06-2022
  • Changes to the operating hours of COVID-19 vaccination centres , 30-05-2022
  • Changes to the operating hours of the Vaccination Centres against COVID-19 , 18-05-2022
  • Availability of Paxlovid for prescription to patients with mild/moderate COVID-19 disease , 11-05-2022
  • Announcement by the Ministry of Health on the administration of a booster/4th dose to vulnerable groups of the population , 10-05-2022
  • Administration of a booster/4th dose to persons over 60 years of age , 22-04-2022
  • Issuance of the vaccination and recovery EUDCC European Digital Certificate for Turkish Cypriots , 20-04-2022
  • Administration of a booster/4th dose through appointment or through walk-in vaccination centres , 19-04-2022
  • Operating hours and places of vaccination centres for the administration of the booster/4th dose of the vaccine to persons of 70 years and over , 12-04-2022
  • Announcement by the Ministry of Health on the administration of the booster/4th dose of the vaccine to persons aged 70 years and over , 11-04-2022
  • 4th dose vaccination against COVID-19 for homebound* patients who have not previously been vaccinated through the domiciliary immunization service for COVID-19 , 11-04-2022
  • 4th dose vaccination against COVID-19 for homebound* patients who have already received their previous doses through the domiciliary immunization service for COVID-19 , 11-04-2022
  • Announcement by the Ministry of Health on the administration of the booster vaccine dose against COVID-19 , 29-03-2022
  • EMA recommends authorisation of COVID-19 medicine Evusheld , 28-03-2022
  • Announcement by the Ministry of Health on the decisions of the Council of Ministers regarding COVID-19 vaccine boosters , 22-03-2022
  • Vaccine Covid-19 NUVAXOVID - General instructions for the public , 15-03-2022
  • Recommendations of the National Vaccination Advisory Committee of the Ministry of Health , 14-03-2022
  • Appointment availability for the Nuvaxovid vaccine via the vaccination portal , 08-03-2022
  • EMA recommends approval of Spikevax for children aged 6 to 11 , 28-02-2022
  • EMA recommends authorisation of booster doses of Comirnaty from 12 years of age , 28-02-2022
  • Operation of a Vaccination Centre in Larnaka Old Hospital as replacement of the Larnaka Port Vaccination Centre , 25-02-2022
  • Changes to the operating hours of the Vaccination Centres as of Monday 21 February 2022 , 18-02-2022
  • EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty in adolescents , 09-02-2022
  • COVID-19 vaccination portal software upgraded , 07-02-2022
  • Change of operating hours of the vaccination centres against COVID-19 as of 7 February 2022 , 03-02-2022
  • *Updated* COVID-19: EMA recommends conditional marketing authorisation for Paxlovid , 31-01-2022
  • Vaccinations of children aged 5-11 in cooperation with the Paediatric Society of Cyprus , 26-01-2022
  • Announcement by the Ministry of Health for the Vaccination Plan against COVID-19 , 17-01-2022
  • Preliminary data indicate COVID-19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron variant , 12-01-2022
  • EMA receives application for conditional marketing authorisation for Paxlovid (PF-07321332 and ritonavir) for treating patients with COVID-19 , 10-01-2022
  • Revised operating hours of Ammochostos Vaccination Centre — Change of self-test availability hours at Lemesos Maternity Centre , 04-01-2022
  • Vaccinations of children aged 5-11 years in cooperation with the Cyprus Paediatric Society , 28-12-2021
  • Administration of the 3rd/booster dose available to students at all walk-in centres on 27 and 28 December , 22-12-2021
  • Nuvaxovid COVID-19 vaccine (recombinant, adjuvanted) , 21-12-2021
  • Temporary operation of Latsia Vaccination Centre only for scheduled appointments , 20-12-2021
  • EMA recommends Nuvaxovid for authorisation in the EU , 20-12-2021
  • EMA recommends approval for use of Kineret in adults with COVID-19 , 17-12-2021
  • COVID-19: EMA recommends authorisation of antibody medicine Xevudy , 17-12-2021
  • EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19 , 17-12-2021
  • Increase in manufacturing capacity for COVID-19 vaccines from Janssen, Moderna and BioNTech/Pfizer , 17-12-2021
  • COVID-19 Vaccine Janssen: EMA recommendation on booster dose , 15-12-2021
  • EMA reviewing new data on effectiveness of Lagevrio (molnupiravir) for the treatment of COVID-19 , 15-12-2021
  • Interval before COVID-19 booster shot reduced to five months and two weeks , 14-12-2021
  • The Vaccination Portal is available for vaccination appointments with the 2nd dose of the Johnson & Johnson vaccine , 10-12-2021
  • EMA and ECDC recommendations on heterologous vaccination courses against COVID-19 , 10-12-2021
  • Administration of the booster/3rd dose of the vaccine against COVID-19 for individuals aged 18 and over , 07-12-2021
  • EMA recommends approval for use of RoActemra in adults with severe COVID-19 , 07-12-2021
  • Increase in manufacturing capacity for COVID-19 vaccine from AstraZeneca , 02-12-2021
  • EMA starts rolling review of Valneva’s COVID-19 vaccine (VLA2001) , 02-12-2021
  • Administration of the booster/3rd dose of the vaccine against COVID-19 for individuals aged 30 and over , 29-11-2021
  • EMA evaluating data on booster dose of COVID-19 Vaccine Janssen , 23-11-2021
  • EMA starts review of Paxlovid for treating patients with COVID-19 , 22-11-2021
  • EMA issues advice on use of Lagevrio (molnupiravir) for the treatment of COVID-19 , 22-11-2021
  • EMA receives application for marketing authorisation for Xevudy (sotrovimab) for treating patients with COVID-19 , 19-11-2021
  • Extension of working hours at walk-in vaccination centres , 19-11-2021
  • EMA receives application for conditional marketing authorisation of Novavax’s COVID-19 vaccine, Nuvaxovid , 17-11-2021
  • Administration of a booster dose for individuals aged 40 years and over, begins , 16-11-2021
  • Council of Ministers: Administration of a booster dose of a COVID-19 vaccine for the population aged 18 years and over , 15-11-2021
  • EMA starts evaluating use of COVID-19 vaccine Spikevax in children aged 6 to 11 , 10-11-2021
  • Booster dose administration procedure for people who were vaccinated with Johnson&Johnson vaccine, for diabetics and for people aged 50 and over , 05-11-2021
  • Home administration of a booster dose of the vaccine against COVID-19 to bedridden patients , 02-11-2021
  • Booster vaccination against COVID-19 for homebound patients who have already received 1st and 2nd doses - FORM A , 02-11-2021
  • Booster vaccination against COVID-19 for homebound patients who have not previously been vaccinated - FORM B , 02-11-2021
  • Extension of measures against the spread of COVID-19 — A booster dose available for individuals vaccinated with J&J , 27-10-2021
  • Spikevax: EMA recommendation on booster dose , 26-10-2021
  • Vaccinations with the 3rd dose begin for people aged 60 years and over , 18-10-2021
  • Council of Ministers: The age limit for the administration of the booster/3rd dose is reduced to 60 and new vulnerable groups are added , 15-10-2021
  • EMA ends rolling review of CVnCoV COVID-19 vaccine following withdrawal by CureVac AG , 13-10-2021
  • Vaccination portal reopens as of 15 October for arrangement of vaccination appointments with 1st and 3rd doses , 13-10-2021
  • Ministry of Health proceeds with the administration of the 3rd dose of COVID-19 vaccine to persons 65 years of age and older , 12-10-2021
  • Large walk-in center for citizens’ vaccination to operate in Lemesos on 10 October , 07-10-2021
  • Vaccination Portal at the disposal of people aged 70 years and over as of 8 October , 07-10-2021
  • Comirnaty and Spikevax: EMA recommendations on extra doses and boosters , 04-10-2021
  • Vaccination Portal opens for 3rd dose vaccination appointments , 02-10-2021
  • Vaccination with the 3rd dose for citizens aged 83 and over , 23-09-2021
  • Gradual vaccination with 3rd dose for individuals aged 65 and over to begin at walk-in vaccination centres , 21-09-2021
  • Efforts to promote COVID-19 vaccination are intensifying , 15-09-2021
  • Vaccination Centres re-open every Saturday for the best service of school and university students , 09-09-2021
  • Vaccination procedure with 3rd dose for specific groups of the population , 06-09-2021
  • EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty , 06-09-2021
  • ECDC and EMA highlight considerations for additional and booster doses of COVID-19 vaccines , 02-09-2021
  • Full vaccination is key to protecting against serious COVID-19, EMA and ECDC say , 05-08-2021
  • Vaccination of non-registered citizens or beneficiaries of the General Healthcare System through the “walk-in” centres , 03-08-2021
  • Document for the vaccination of citizens who are not GHS beneficiaries , 03-08-2021
  • Vaccination procedure for minors aged 12 to 17 , 30-07-2021
  • COVID-19 Vaccine Janssen: Guillain-Barré syndrome listed as a very rare side effect , 23-07-2021
  • Scheduling of appointments for vaccination against COVID-19 through the telephone lines of the Ministry of Health , 22-07-2021
  • Administration of 2nd dose of covid vaccine in Cyprus to individuals who have been vaccinated with 1st dose abroad , 20-07-2021
  • Operation of hotlines for the rescheduling of appointments for the administration of the 2nd dose , 17-07-2021
  • Access of citizens to vaccination is facilitated through "walk-in" vaccination centres , 14-07-2021
  • Answers to frequently asked questions about the vaccines against COVID-19 by the Pharmaceutical Services of the Ministry of Health , 13-07-2021
  • Vaccination procedure for persons aged 16 and 17 years , 09-07-2021
  • EMA advises against use of COVID-19 Vaccine Janssen in people with history of capillary leak syndrome , 09-07-2021
  • Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis , 09-07-2021
  • The Ministry of Health proceeds with vaccination of 16 and 17 year olds who are not registered in GeSY , 01-07-2021
  • Written Consent Document of Parents / Legal Guardians for Vaccination of Minors against COVID-19 , 01-07-2021
  • Effort to increase vaccination coverage continues – The target for the vaccination of 65% of the population with the 1st dose has been achieved , 01-07-2021
  • The Ministry of Health proceeds with the vaccination of individuals aged 16 and 17 , 28-06-2021
  • The pandemic will be treated effectively only through vaccination – Appointments available for all people over the age of 18 , 14-06-2021
  • Vaxzevria COVID Vaccine – EMA advises against use in people with history of capillary leak syndrome , 11-06-2021
  • COVID-19 vaccines: Update on ongoing evaluation of myocarditis and pericarditis , 11-06-2021
  • Vaccination is our main weapon to exit the health crisis , 10-06-2021
  • Issuance of SARS-CoV-2 Vaccination Certificate , 07-06-2021
  • EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome , 07-06-2021
  • Over 54% of the population has received the 1st dose of the vaccine – Schedule for the Vaccination Portal for the period 4-12 June , 03-06-2021
  • Getting closer to the target for vaccination of 65% of the population with at least the first dose – Information on vaccination appointments , 29-05-2021
  • First COVID-19 vaccine approved for children aged 12 to 15 in EU , 28-05-2021
  • Announcement by the Ministry of Health on the recommendations of the Scientific Advisory Committee for the AstraZeneca vaccine , 26-05-2021
  • Citizens gradually informed about AstraZeneca 2nd dose rescheduling , 26-05-2021
  • Vaccination coverage increases, the population is being shielded against COVID-19 , 23-05-2021
  • Threshold of half a million vaccinations surpassed - Schedule of appointments for 24-29 May , 22-05-2021
  • Vaxzevria COVID-19 Vaccine: Further advice on blood clots and low blood platelets , 21-05-2021
  • Sinopharm vaccine (BBIBP COVID-19) in the category of vaccines accepted by the Republic of Cyprus , 20-05-2021
  • Vaccinations are at a more advanced stage compared to the initial plan – The Vaccination Portal opens for ages 18-21 , 14-05-2021
  • AstraZeneca vaccine can be administered to individuals aged 20 years and over by their Personal Doctors , 13-05-2021
  • The vaccination plan now focuses on young people – Answers to basic questions , 13-05-2021
  • Cyprus ranks 4th among EU member states in terms of administration of vaccine doses per 100 inhabitants , 12-05-2021
  • The appointment process for the 20-29 age group proceeds at a faster pace – Vaccination coverage by District , 10-05-2021
  • Vaccination Portal opens for people aged 29 and 30 , 09-05-2021
  • Schedule for the arrangement of vaccination appointments against COVID-19 on 8 and 9 May, ages 31-34 , 07-05-2021
  • The Pharmaceutical Services provide answers to frequently asked questions about the vaccines against COVID-19 , 05-05-2021
  • Changes in the process of arranging appointments through the COVID-19 Vaccination Portal as of 06/05/2021 , 04-05-2021
  • Priority for vaccination against COVID-19 for the age group of 30-38 – Schedule for 4-7 May , 03-05-2021
  • Schedule for the arrangement of vaccination appointments against COVID-19 for April 29-30 and May 4th , 28-04-2021
  • Vaccination against COVID-19 – Answers to frequently asked questions , 27-04-2021
  • Period of administration of 2nd dose of AstraZeneca vaccine reduced to eight weeks , 27-04-2021
  • National Vaccination Plan is in progress – Schedule for the period of 27-29 April , 26-04-2021
  • Vaccination coverage of the population continues – 20% of citizens have been vaccinated with the 1st dose of the vaccine , 25-04-2021
  • Administration of the AstraZeneca vaccine by Personal Doctors to beneficiaries aged 30 and over , 22-04-2021
  • Updated schedule for the period 22-25 April vaccination program against COVID-19 , 21-04-2021
  • COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets , 20-04-2021
  • The implementation of the National Vaccination Plan continues – Appointments available for individuals aged 51-52 , 18-04-2021
  • Press conference on the next steps of the vaccination plan , 16-04-2021
  • 200,000 vaccinations administered in Cyprus until today – Priority to 53-54 age group for vaccination appointments on 16-17 April , 15-04-2021
  • Janssen vaccine will not be administered pending the completion of the investigation of thrombosis cases in the USA , 14-04-2021
  • AstraZeneca’s COVID-19 vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets , 14-04-2021
  • No self-isolation required for close contacts who have been vaccinated , 14-04-2021
  • General instructions to persons vaccinated - Janssen (Johnson&Johnson) Vaccine , 14-04-2021
  • Requests for the COVID-19 home vaccination of bedridden individuals end on 16 April , 13-04-2021
  • Vaccination appointment programme for the period 13-17 April , 12-04-2021
  • Vaccination portal opens on Sunday for individuals belonging to specific vulnerable groups , 10-04-2021
  • Access to the Vaccination Portal for the arrangement of appointments by individuals aged 59 and 60 , 09-04-2021
  • AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets , 07-04-2021
  • 19,378 appointments to be made available for the vaccination of persons aged 61 and over , 06-04-2021
  • Vaccination Portal opens for individuals who use biological agents or other immunosuppressive medicines , 04-04-2021
  • AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues , 31-03-2021
  • Vaccination Portal to be made available for people aged 64 and over, on 1 April , 31-03-2021
  • Vaccination Portal available until 31 March for patients with Diabetes Mellitus and Severe Obesity , 31-03-2021
  • Over 19,000 vaccination appointments for individuals with Diabetes Mellitus and Severe Obesity , 28-03-2021
  • Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna , 26-03-2021
  • COVID-19 Vaccine AstraZeneca – Update on ongoing evaluation of blood clot cases , 26-03-2021
  • A total of 310,000 individuals will have received at least the 1st dose of a vaccine by the beginning of May , 22-03-2021
  • Rescheduling of postponed appointments for vaccination with the AstraZeneca vaccine , 21-03-2021
  • The Vaccination Portal will be made available for people aged 66 and over on 20 – 21 March , 19-03-2021
  • AstraZeneca vaccinations to be carried out normally , 18-03-2021
  • COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets , 18-03-2021
  • Investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events continues , 16-03-2021
  • Postponement of vaccinations with the AstraZeneca vaccine until 18 March , 15-03-2021
  • EMA’s Safety Committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events – further update , 15-03-2021
  • Answers to frequently asked questions on COVID-19 Vaccine Janssen , 11-03-2021
  • EMA recommends COVID-19 Vaccine Janssen (Johnson&Johnson) for authorisation in the EU , 11-03-2021
  • COVID-19 Vaccine AstraZeneca: PRAC preliminary view suggests no specific issue with batch used in Austria , 11-03-2021
  • Vaccination Portal to be made available for people aged 67 and over – 22,808 vaccination appointments , 08-03-2021
  • EMA starts rolling review of the Sputnik V COVID-19 vaccine , 04-03-2021
  • Vaccination Portal to be made available for people aged 69 and over – 17,496 vaccination appointments , 02-03-2021
  • The objectives of the National Vaccination Plan are being achieved – More than 64,000 vaccines have been administered by the 23rd February , 24-02-2021
  • As of 23 February, 16,904 vaccination appointments will be made available for people aged 71 and over , 22-02-2021
  • COVID-19 Vaccination of specific categories of the population based on serious illness risk factors , 19-02-2021
  • National Vaccination Plan for COVID-19: 9.096 appointments for persons aged 74 and over , 16-02-2021
  • Statement by the Minister of Health, Mr Constantinos Ioannou, at the press conference on the National Vaccination Plan for COVID-19 , 12-02-2021
  • EMA starts rolling review of CureVac’s COVID-19 vaccine (CVnCoV) , 12-02-2021
  • 9,264 Vaccination appointments made available for people over the age of 76 , 11-02-2021
  • Clarifications regarding the administration of AstraZeneca vaccine to specific age groups , 10-02-2021
  • Third phase of the National Vaccination Plan for COVID-19 begins with appointments made available for people over the age of 79 , 09-02-2021
  • General instructions to persons vaccinated - AstraZeneca Vaccine , 09-02-2021
  • EMA starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373) , 04-02-2021
  • Vaccination Portal to be made available to citizens over the age of 83 , 02-02-2021
  • Vaccination appointments for citizens over the age of 84 – 7,790 vaccine doses administered during the week of 23-29 January , 30-01-2021
  • EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU , 29-01-2021
  • Answer to frequently-asked questions on COVID-19 Vaccine AstraZeneca , 29-01-2021
  • COVID-19 vaccine safety update for Comirnaty , 29-01-2021
  • First COVID-19 vaccine safety update published , 29-01-2021
  • Clarification of Comirnaty dosage interval , 29-01-2021
  • Vaccination Portal to be made available to citizens over the age of 86 as of 29 January – New appointments as of 1st February , 28-01-2021
  • Vaccination Portal to be made available to citizens over the age of 88 as of 27 January , 26-01-2021
  • General instructions to persons vaccinated - Moderna Vaccine , 13-01-2021
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca , 12-01-2021
  • EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU , 06-01-2021
  • Answers to frequently asked questions on COVID-19 Vaccine Moderna , 06-01-2021
  • GHS Beneficiary Portal User Manual for COVID-19 Vaccination , 04-01-2021
  • Application process for the registration to Covid-19 Vaccinations’ Portal of citizens who are not GHS beneficiaries , 04-01-2021
  • Document for the Registration of Citizens who are not GHS beneficiaries, to the Cyprus Portal for COVID-19 vaccinations , 04-01-2021
  • Update on rolling review of AstraZeneca’s COVID-19 vaccine , 31-12-2020
  • General instructions to persons vaccinated - Comirnaty (Pfizer/BioNTeck) Vaccine , 28-12-2020
  • First batch of Pfizer-BioNTech vaccines to be delivered on 26 December – vaccinations to begin on 27 December , 22-12-2020
  • Answers to frequently asked questions about Comirnaty - COVID-19 mRNA vaccine (nucleoside modified) , 22-12-2020
  • EMA recommends first COVID-19 vaccine for authorisation in the EU , 21-12-2020
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application , 16-12-2020
  • Answers to frequently asked questions about vaccines/vaccination against COVID-19 , 15-12-2020
  • The National Vaccination Plan for COVID-19 was presented , 15-12-2020
  • National Vaccination Plan for Covid-19 , 15-12-2020